OrthoPediatrics (NASDAQ:KIDS) Price Target Lowered to $24.00 at Truist Financial

OrthoPediatrics (NASDAQ:KIDS) had its price target reduced by Truist Financial from $26.00 to $24.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a hold rating on the stock.

KIDS has been the subject of a number of other reports. Lake Street Capital began coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a “buy” rating and a $37.00 price objective for the company. Stifel Nicolaus lowered their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.00.

OrthoPediatrics Price Performance

KIDS stock opened at $21.16 on Friday. The stock’s 50 day moving average price is $24.20 and its 200 day moving average price is $24.76. The firm has a market cap of $513.91 million, a P/E ratio of -17.20 and a beta of 1.17. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. OrthoPediatrics has a 1 year low of $20.78 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The business had revenue of $52.67 million for the quarter, compared to the consensus estimate of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same period in the prior year, the business earned ($0.23) earnings per share. On average, sell-side analysts expect that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now directly owns 110,767 shares in the company, valued at $2,753,667.62. This represents a 4.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the transaction, the insider now directly owns 148,788 shares in the company, valued at $3,698,869.68. This represents a 3.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,732 shares of company stock valued at $589,978. Insiders own 31.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KIDS. Quarry LP purchased a new stake in OrthoPediatrics during the third quarter worth approximately $25,000. R Squared Ltd purchased a new stake in OrthoPediatrics during the 4th quarter worth $48,000. KLP Kapitalforvaltning AS acquired a new stake in OrthoPediatrics in the 4th quarter valued at $79,000. BNP Paribas Financial Markets raised its position in OrthoPediatrics by 125.1% in the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after purchasing an additional 1,929 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new position in shares of OrthoPediatrics during the fourth quarter worth about $171,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.